EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Leveraging Kinesin Family as Key Regulators of Malignant Progression and the Immunometabolic Niche for Precision Oncology

Leyi Li iD, Jing Li iD, Xinyi Zhao iD, Haohan Zhang iD, Qibin Song iD, Yuchao Dan iD, Lan Li iD, Jie Wu iD, Chao Yang iD, Junju He iD, Bin Xu iD

Technology in Cancer Research & Treatment · 2026-07 · 25

DOI: 10.1177/15330338261470918 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Technology in Cancer Research & Treatment, online erschienen am 21.07.2026. Verfasst von Leyi Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China. Hauptthemen laut MEDLINE: Kinesins, Neoplasms, Precision Medicine. Die Arbeit nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China NSFC, The Cross-Innovation Talent Project of Renmin Hospital of Wuhan University, Hubei Provincial Natural Science Foundation Joint Fund Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Malignant tumors impose a substantial burden on global health, with an urgent unmet need for effective targets to advance precision therapy. As evolutionarily conserved microtubule motor proteins, the kinesin family (KIF) orchestrates fundamental cellular processes (e.g., intracellular transport, cell division) and canonical signaling pathways, including Wnt and Hippo. Notably, recent studies have uncovered their emerging role in regulating tumor metabolism and reshaping the immune microenvironment, where dysregulated KIF expression drives aberrant tumor proliferation. Based on current research, here we synthesize the latest mechanistic insights into KIF-mediated tumor regulation and evaluate their translational potential as next-generation therapeutic targets and biomarkers for precision cancer therapy. KIF-targeted inhibitors have entered clinical trials across multiple cancer types, holding promise as novel anticancer agents to suppress tumor growth and progression, thereby providing valuable therapeutic options for clinical oncology practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

KinesinsNeoplasmsPrecision MedicineHumansTumor MicroenvironmentDisease ProgressionAnimalsSignal TransductionMolecular Targeted TherapyBiomarkers, TumorMetabolic ReprogrammingGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

anti-cancer therapy resistancecancer progressionkinesin familymetabolic reprogrammingtumor immune microenvironment

Substanzen

KinesinsBiomarkers, Tumor

Autor:innen und Institutionen

  • Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China.
  • Department of Oncology, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang Central Hospital, Xiangyang, China.

ORCID-Profile: Leyi Li, Jing Li, Xinyi Zhao, Haohan Zhang, Qibin Song, Yuchao Dan, Lan Li, Jie Wu, Chao Yang, Junju He, Bin Xu

Förderung

  • National Natural Science Foundation of China NSFC
  • The Cross-Innovation Talent Project of Renmin Hospital of Wuhan University
  • Hubei Provincial Natural Science Foundation Joint Fund Project
  • Xiangyang Central Hospital’s Institutional Research Project

Zitieren

APA

Li, L., Li, J., Zhao, X., Zhang, H., Song, Q., Dan, Y., Li, L., Wu, J., Yang, C., He, J., & Xu, B. (2026). Leveraging Kinesin Family as Key Regulators of Malignant Progression and the Immunometabolic Niche for Precision Oncology. Technology in Cancer Research & Treatment, 25. https://doi.org/10.1177/15330338261470918

Vancouver

Li L, Li J, Zhao X, Zhang H, Song Q, Dan Y, et al. Leveraging Kinesin Family as Key Regulators of Malignant Progression and the Immunometabolic Niche for Precision Oncology. Technology in Cancer Research & Treatment. 2026;25. doi:10.1177/15330338261470918

BibTeX
@article{Li2026,
  author = {Li, Leyi and Li, Jing and Zhao, Xinyi and Zhang, Haohan and Song, Qibin and Dan, Yuchao and Li, Lan and Wu, Jie and Yang, Chao and He, Junju and Xu, Bin},
  title = {Leveraging Kinesin Family as Key Regulators of Malignant Progression and the Immunometabolic Niche for Precision Oncology},
  journal = {Technology in Cancer Research & Treatment},
  year = {2026},
  volume = {25},
  doi = {10.1177/15330338261470918}
}
Kostenlos starten →